Canaccord Genuity reiterates a 'Buy' rating on AVEO Pharmaceuticals (Nasdaq: AVEO), raises PT from $14 to $23.

Canaccord analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE